Phase 3 study of the efficacy, pharmacokinetics, immunogenicity and safety of von Willebrand Factor/Factor VIII concentrate in patients with severe von Willebrand Disease under 6 years of age - Jain, A; Weisz, T-E; Solomon, C (Hämostaseologie, 2023)